ORPHA:98848
Indolent systemic mastocytosis
Publications
692
82.6th percentile
Trials
10
Interventional, condition-specific
Researchers
1,083
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare, usually benign, chronic, form of systemic mastocytosis (SM) characterized by an abnormal accumulation of neoplastic mast cells (MCs) mainly in the bone marrow (BM) but also in other organs or tissues such as preferably the skin.
How rare: 1-5 / 10 000 — about one to five people per ten thousand (still uncommon, but less ultra-rare).
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0020331
- UMLS:C0272203
- NCIT:C9286
Additional Mondo synonyms (3)
ISM · indolent systemic mastocytosis (morphologic abnormality) · ism
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
692 matched papers (465 in last 10 years) Source
- Phenotype characterisedPresent
21 HPO annotations (e.g. Hematological neoplasm; Abnormal bone marrow cell morphology; Abnormal skin morphology) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
10 matched on ClinicalTrials.gov (1 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
21
Associated phenotypes · MONDO:0020331
- Hematological neoplasm
- Abnormal bone marrow cell morphology
- Abnormal skin morphology
- Increased CD25+ mast cell proportion
- Abnormal mast cell morphology
Showing 5 of 21 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
692
692 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
692 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
465 in the last 10 years · medium confidence · 82.6th percentile (publications denominator)
Phrase hits: 692 · MeSH hits: 0
Who's working on it?
1,083
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Akin C20 papers · 2026
Department of Internal Medicine, Allergy Immunology, University of Michigan, Ann Arbor, Mich. Electronic address: cemakin@med.umich.edu.
Papers in Europe PMC - 02Reiter A14 papers · 2026
Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Papers in Europe PMC - 03Castells M13 papers · 2026
Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Mass; Harvard Medical School, Boston, Mass. Electronic address: mcastells@bwh.harvard.edu.
Papers in Europe PMC - 04Hartmann K13 papers · 2026
Department of Dermatology, University of Cologne, Cologne, Germany; Division of Allergy, Department of Dermatology, and Department of Biomedicine, University of Basel, Basel, Switzerland.
Papers in Europe PMC - 05Valent P13 papers · 2025
Department of Internal Medicine I, Division of Hematology and Hemostaseology, and Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
Papers in Europe PMC - 06Niedoszytko M12 papers · 2025
Department of Allergology, Medical University of Gdańsk, Gdańsk, Poland.
Papers in Europe PMC - 07Sabato V12 papers · 2026
Faculty of Medicine and Health Sciences, Department of Immunology-Allergology-Rheumatology, University of Antwerp and Antwerp University Hospital, Antwerp, Belgium.
Papers in Europe PMC - 08Siebenhaar F12 papers · 2026
Dermatological Allergology, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Papers in Europe PMC - 09George TI11 papers · 2026
Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT, USA.
Papers in Europe PMC - 10Bonadonna P10 papers · 2026
Allergy Unit, Verona University Hospital, Verona, Italy.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
10
interventional trials for this specific condition
10 interventional trials matched this specific condition name; 1 currently recruiting in our sample. 27 trials are registered for systemic mastocytosis, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
10 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 92.5th percentile).
medium confidence · 92.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
10 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT04910685·RECRUITING·(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
Not reviewed·Conditions: Indolent Systemic Mastocytosis · Smoldering Systemic Mastocytosis·Matched via name phrase
Broader category: systemic mastocytosis
27
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT04996875·RECRUITING·(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Not reviewed·Conditions: Advanced Systemic Mastocytosis (AdvSM) · SM With an Associated Hematologic Neoplasm (SM-AHN) · Mast Cell Leukemia (MCL) · Aggressive Systemic Mastocytosis (ASM)·Matched via name phrase
- NCT06327685·RECRUITING·Avapritinib With Decitabine in Patients With SM-AHN
Not reviewed·Conditions: Systemic Mastocytosis With an Associated Hematologic Neoplasm·Matched via name phrase
Observational and natural-history studies
6 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT07264959·RECRUITING·An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)
Not reviewed·Conditions: Indolent Systemic Mastocytosis·Matched via name phrase
- NCT07255638·RECRUITING·A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany
Not reviewed·Conditions: Indolent Systemic Mastocytosis·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 5 · after dedupe 5 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 5 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (5)
- ctis·2023-509111-89-00·Authorised, ongoing·The use of dupilumab in treatment of indolent systemic mastocytosis with skin involvement
skipped — LLM skipped (--skip-llm)
- ctis·2024-516728-32-00·Authorised, ongoing·A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis
skipped — LLM skipped (--skip-llm)
- ctis·2024-518594-33-00·Authorised, ongoing·Hydroxychloroquine in isolated cutaneous mastocytosis patients or indolent systemic mastocytosis with associated skin involvement patients: proof of concept study (HCQMa)
skipped — LLM skipped (--skip-llm)
- ctis·2024-512585-34-00·Expired·A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU 285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy
skipped — LLM skipped (--skip-llm)
- ctis·2024-514467-26-00·Expired·A Phase 2 Multicenter Study of TL-895 in Subjects with Myelofibrosis, Indolent Systemic Mastocytosis, Monoclonal Mast Cell Activation Syndrome, or Non-Monoclonal Mast Cell Activation Syndrome
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Indolent systemic mastocytosis — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Indolent systemic mastocytosis" OR "indolent systemic mastocytosis (morphologic abnormality)"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Indolent systemic mastocytosis" OR "indolent systemic mastocytosis (morphologic abnormality)"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 10 interventional · 6 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"systemic mastocytosis"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: ISM
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T05:35:00.480Z
